Endometrial cancer: agreement between P53 immunohistochemistry and TP53 mutational analysis ?

Abstract

peer reviewedAbnormal expression of p53 in IHC can be considered as a reliable surrogate test for TP53 mutation. Moreover, p53 IHC is quicker, easier to perform and less expensive. Nevertheless, based on a 25% rate of false positivity, consideration should be given to confirm TP53 status for all patients with abnormal p53 IHC